R
Rachael Hunter
Researcher at Swansea University
Publications - 16
Citations - 355
Rachael Hunter is an academic researcher from Swansea University. The author has contributed to research in topics: Thematic analysis & Psychosocial. The author has an hindex of 5, co-authored 16 publications receiving 134 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.
TL;DR: CO VID-19 confidential gave an outlet for unprompted and uncensored stories of healthcare workers in the context of COVID-19, with common themes the shock of the virus, staff sacrifice and dedication and a hierarchy of power and inequality within the healthcare system.
Journal ArticleDOI
“Post-thrombotic panic syndrome”: A thematic analysis of the experience of venous thromboembolism
TL;DR: The psychosocial impact of VTE as life-changing and traumatic, encompassing a dynamic duality of trauma and growth, is demonstrated, highlighting a potential role for health care professionals in identifying and supporting individuals at risk of post-traumatic stress.
Journal ArticleDOI
Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community.
TL;DR: The data demonstrate the psychosocial impact of VTE and its diagnosis as physically and psychologically challenging, and individuals reported being forever changed by the experience.
Journal ArticleDOI
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
Nikos Evangelou,Afagh Garjani,Roshan dasNair,Rachael Hunter,Katherine A Tuite-Dalton,Elaine M Craig,W. J. Rodgers,Alasdair Coles,Ruth Dobson,Martin Duddy,David V. Ford,Stella Hughes,Owen R Pearson,Linda A Middleton,David Rog,Emma C. Tallantyre,Tim Friede,Rodden M. Middleton,Richard Nicholas +18 more
TL;DR: In the early phases of the UK COVID-19 outbreak, in the absence of clear evidence about the risks for people with multiple sclerosis (pwMS) and those taking immunomodulatory disease-modifying therapies (DMT), a community-based study was launched to capture the picture of CO VID-19 among pwMS and their risk of contracting the disease.
Journal ArticleDOI
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
Afagh Garjani,Rodden M. Middleton,Rachael Hunter,Katherine A Tuite-Dalton,Alasdair Coles,Ruth Dobson,Martin Duddy,Stella Hughes,Owen R Pearson,David Rog,Emma C. Tallantyre,Roshan das Nair,Richard Nicholas,Nikos Evangelou,Nikos Evangelou +14 more
TL;DR: In this paper, the authors investigated the impact of the coronavirus disease 2019 (COVID-19) infection on new and pre-existing symptoms of multiple sclerosis (MS) in a prospective cohort study.